175 related articles for article (PubMed ID: 16236615)
1. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
[TBL] [Abstract][Full Text] [Related]
2. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
3. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Fanale MA; Cheah CY; Rich A; Medeiros LJ; Lai CM; Oki Y; Romaguera JE; Fayad LE; Hagemeister FB; Samaniego F; Rodriguez MA; Neelapu SS; Lee HJ; Nastoupil L; Fowler NH; Turturro F; Westin JR; Wang ML; McLaughlin P; Pinnix CC; Milgrom SA; Dabaja B; Horowitz SB; Younes A
Blood; 2017 Jul; 130(4):472-477. PubMed ID: 28522441
[TBL] [Abstract][Full Text] [Related]
4. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
5. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
[No Abstract] [Full Text] [Related]
6. High efficacy of the CHOP + rituximab association in a case of primary rectal non-Hodgkin lymphoma (NHL).
Vassallo E; Di Noto L; Palmeri L; Vaglica M; Pancera G; Palmeri S
Leuk Lymphoma; 2006 Aug; 47(8):1686-7. PubMed ID: 16966287
[No Abstract] [Full Text] [Related]
7. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
9. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
10. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
[TBL] [Abstract][Full Text] [Related]
11. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
14. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
15. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
Hawkes EA; Wotherspoon A; Cunningham D
Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
18. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under
Gutsch J; Werthmann PG; Rosenwald A; Kienle GS
Anticancer Res; 2018 Sep; 38(9):5363-5369. PubMed ID: 30194190
[TBL] [Abstract][Full Text] [Related]
19. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
20. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
